Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?
The prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore, early identification and intervention play a crucial role. With the deepening understanding of the etiology of metabolic diseases, novel thera...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1498288/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592143729819648 |
|---|---|
| author | Jinyang An Donghua Fu Ximei Chen Conghui Guan Conghui Guan Lingling Li Jia Bai Haihong Lv Haihong Lv |
| author_facet | Jinyang An Donghua Fu Ximei Chen Conghui Guan Conghui Guan Lingling Li Jia Bai Haihong Lv Haihong Lv |
| author_sort | Jinyang An |
| collection | DOAJ |
| description | The prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore, early identification and intervention play a crucial role. With the deepening understanding of the etiology of metabolic diseases, novel therapeutic targets are emerging for the treatment of obesity, lipid metabolism disorders, cardiovascular and cerebrovascular diseases, glucose metabolism disorders, and other related metabolic conditions. IL-27, as a multi-potent cytokine, holds great promise as a potential candidate target in this regard. This article provides a comprehensive review of the latest findings on IL-27 expression and signal transduction in the regulation of immune inflammatory cells, as well as its implications in obesity and other related metabolic diseases. Furthermore, it explores the potential of IL-27 as a novel therapeutic target for the treatment of obesity and metabolic disorders. Finally, an overview is presented on both the opportunities and challenges associated with targeting IL-27 for therapeutic interventions. |
| format | Article |
| id | doaj-art-5300d9f51ba64d629f708657effb5422 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-5300d9f51ba64d629f708657effb54222025-01-21T14:11:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14982881498288Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?Jinyang An0Donghua Fu1Ximei Chen2Conghui Guan3Conghui Guan4Lingling Li5Jia Bai6Haihong Lv7Haihong Lv8The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Endocrinology, The People’s Hospital of Yuzhong County, Lanzhou, Gansu, ChinaDepartment of General Medicine, Zhengzhou Yihe Hospital affiliated to Henan University, Zhengzhou, Henan, ChinaThe First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, ChinaThe First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, ChinaThe First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, ChinaThe First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, ChinaThe prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore, early identification and intervention play a crucial role. With the deepening understanding of the etiology of metabolic diseases, novel therapeutic targets are emerging for the treatment of obesity, lipid metabolism disorders, cardiovascular and cerebrovascular diseases, glucose metabolism disorders, and other related metabolic conditions. IL-27, as a multi-potent cytokine, holds great promise as a potential candidate target in this regard. This article provides a comprehensive review of the latest findings on IL-27 expression and signal transduction in the regulation of immune inflammatory cells, as well as its implications in obesity and other related metabolic diseases. Furthermore, it explores the potential of IL-27 as a novel therapeutic target for the treatment of obesity and metabolic disorders. Finally, an overview is presented on both the opportunities and challenges associated with targeting IL-27 for therapeutic interventions.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1498288/fullil-27obesitymetabolic diseasescardiovascular diseasesabnormal glucose metabolismlipid metabolism disorder |
| spellingShingle | Jinyang An Donghua Fu Ximei Chen Conghui Guan Conghui Guan Lingling Li Jia Bai Haihong Lv Haihong Lv Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation? Frontiers in Immunology il-27 obesity metabolic diseases cardiovascular diseases abnormal glucose metabolism lipid metabolism disorder |
| title | Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation? |
| title_full | Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation? |
| title_fullStr | Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation? |
| title_full_unstemmed | Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation? |
| title_short | Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation? |
| title_sort | revisiting the role of il 27 in obesity related metabolic diseases safeguard or perturbation |
| topic | il-27 obesity metabolic diseases cardiovascular diseases abnormal glucose metabolism lipid metabolism disorder |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1498288/full |
| work_keys_str_mv | AT jinyangan revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT donghuafu revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT ximeichen revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT conghuiguan revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT conghuiguan revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT linglingli revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT jiabai revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT haihonglv revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation AT haihonglv revisitingtheroleofil27inobesityrelatedmetabolicdiseasessafeguardorperturbation |